Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab
MEAJO-Middle East African Journal of Ophthalmology. 2012; 19 (4): 432-435
in English
| IMEMR
| ID: emr-151440
ABSTRACT
Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia [RLH] treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Language:
English
Journal:
Middle East Afr. J. Ophthalmol.
Year:
2012
Similar
MEDLINE
...
LILACS
LIS